2. Disease Areas
  3. Infection
  4. Bacterial Infection
  5. Streptococcus Pneumoniae Infection

Streptococcus Pneumoniae Infection

Streptococcus pneumoniae is a Gram-positive bacterium responsible for severe diseases including pneumonia, meningitis, and septicemia, particularly in children and the elderly, with limited efficacy of current pneumococcal vaccines. Over 90 serotypes have been identified based on capsular polysaccharide structure, with approximately 20 serotypes being highly virulent and causing about 90% of pneumococcal infections. In 2016, S. pneumoniae was estimated to cause around 1.2 million deaths globally. Two types of pneumococcal vaccines are currently available to combat this pathogen.

Streptococcus Pneumoniae Infection (11):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-124617A
    AMXT-1501 tetrahydrochloride 2444815-84-1 98.0%
    AMXT-1501 tetrahydrochloride is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 tetrahydrochloride targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 tetrahydrochloride inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 tetrahydrochloride targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 tetrahydrochloride in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 tetrahydrochloride is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.
    AMXT-1501 tetrahydrochloride
  • HY-124617
    AMXT-1501 441022-64-6 99.44%
    AMXT-1501 is a Bacterial agent and polyamine transport system inhibitor. AMXT-1501 targets membrane phospholipids and exhibits antibacterial activity against a variety of Gram-positive and Gram-negative multidrug-resistant bacteria. AMXT-1501 inhibits capsular biosynthesis in Streptococcus pneumoniae. AMXT-1501 targets ornithine decarboxylase and polyamines to inhibit the proliferation of neuroblastoma cells. AMXT-1501 in combination with DFMO (HY-B0744) induces Apoptosis in neuroblastoma cells. AMXT-1501 is applicable to research related to multidrug-resistant bacterial infections, pneumococcal infections, Streptococcus pneumoniae infections, and neuroblastoma.
    AMXT-1501
  • HY-N0241
    Rhodionin 85571-15-9 99.73%
    Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC50=0.761 μM), AChE (IC50=2.43-57.5 μM), and DPPH free radicals (IC50=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA).
    Rhodionin
  • HY-P99122
    Anti-Mouse CD209b Antibody (22D1) 99.00%
    Anti-Mouse CD209b Antibody (22D1) is an anti-mouse CD209b IgG1 antibody inhibitor derived from the host Armenian Hamster. Anti-Mouse CD209b Antibody (22D1) can block SIGN-R1. Anti-Mouse CD209b Antibody (22D1) can be used for the researches of infection, inflammation and immunology, such as toxoplasma infection and pneumonia.
    Anti-Mouse CD209b Antibody (22D1)
  • HY-105049A
    Ceftaroline hydrochloride 98.0%
    Ceftaroline hydrochloride (T-91825 hydrochloride) is a Cephalosporin compound and the active form of TAK-599 (HY-14737). T-91825 is active against both gram-positive and gram-negative bacteria. Ceftaroline hydrochloride has antibacterial activity against MRSA, MRSE, PISP, and PRSP, with MIC90 values of 2 μg/mL, 1 μg/mL, 0.13 μg/mL, and 0.25 μg/mL, respectively.
    Ceftaroline hydrochloride
  • HY-107044
    DK 507k 364069-14-7
    DK 507k is an orally active 8-methoxyquinolone Antibacterial agent. DK 507k targets DNA gyrase subunit A (GyrA) and modulates the function of GyrA. DK 507k inhibits the growth of various Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa and Methicillin (HY-121544)-resistant Staphylococcus aureus. DK 507k eliminates Penicillin-tolerant Streptococcus pneumoniae from the lungs of mice. DK 507k can be used in research related to sepsis and *Streptococcus pneumoniae* pneumonia.
    DK 507k
  • HY-182022
    ZLWH-67 3083425-49-1
    ZLWH-67 is a β-Carboline derivative and Antibacterial agent. ZLWH-67 inhibits DNA synthesis, suppresses biofilm formation, and increases reactive oxygen species (ROS) levels. ZLWH-67 exhibits potent in vitro antibacterial activity against MRSA (MIC = 0.5-4 μg/mL), S. epidermidis (MIC = 4 μg/mL), E. faecalis (MIC = 4-8 μg/mL), and S. pneumoniae (MIC = 16 μg/mL). ZLWH-67 displays anti-MRSA effects in murine skin and pneumonia infection models.
    ZLWH-67
  • HY-N17621
    Chinenol A 633294-59-4
    Chinenol A is an antibacterial agent that can be found in the aerial part of Helwingia chinensis. Chinenol A can be used for the research of bacterial infections (staphylococcus aureus infection, mycobacterium tuberculosis infection, streptococcus pneumonia infection).
    Chinenol A
  • HY-P11616
    WK2
    WK2 is an antibacterial agent. WK2 reduces serum TNF-α production induced by Bacterial infection. WK2 reduces wound size and promotes tissue repair in a skin wound infection model. WK2 exerts anti-inflammatory effects in a pneumonia model. WK2 can be used for research on infectious diseases such as pneumonia caused by bacterial infection.
    WK2
  • HY-180767
    Azithromycin-amide-C3-amide-quinoxaline
    Azithromycin-amide-C3-amide-quinoxaline (Compound 5f) is an Azithromycin (HY-17506) derivative and antibacterial agent. Azithromycin-amide-C3-amide-quinoxaline inhibits topoisoisomerase I with an IC50 of 120.7 μM. Azithromycin-amide-C3-amide-quinoxaline interacts with 70S E. coli ribosome with a Kd of 0.8 nM. Azithromycin-amide-C3-amide-quinoxaline inhibits bacterial translation with an IC50 of 0.7 μM. Azithromycin-amide-C3-amide-quinoxaline shows antibacterial potency against S. pneumonia ATCC 49619, S. aureus ATCC 29213, E. faecalis ATCC 29212 with MICs of 0.06 μg/mL, 2 μg/mL, 0.5 μg/mL, respectively. Azithromycin-amide-C3-amide-quinoxaline exhibits anticancer activity against prostate cancer, colon cancer.
    Azithromycin-amide-C3-amide-quinoxaline
  • HY-W653770
    Desmycosin 11032-98-7
    Desmycosin is a macrolide antibiotic. Desmycosin exhibits biological activity against H. influenzae, S.aureus, S. pneumoniae, and S. pyogenes with MIC values of 4, 1, <0.125, and <0.125 µg/ml, respectively. Desmycosin is an acidic degradation product of tylosin.
    Desmycosin